Spideyboy Thursday, 06/07/18 02:16:29 AM Re: None Post # of 520 In case anyone missed it. Oramed started their 240 participant HbA1c 12 week study in T2DM, last month. It was due to begin in 1Q 2018, so a little delayed but not by much. https://clinicaltrials.gov/ct2/show/NCT03467932?term=oramed&rank=4 This study will be critical for FDA approval to progress to Phase III Study expected to be about 12-18 months. The study data so far in terms of ORMD-0801 on HbA1c is compelling so this study should be more of a confirmatory formality of prior results, (see company presentation slide 27).